The Orphan Drug Act is being exploited by companies like KV Pharmaceuticals to repatent old, cheap compounds and raise prices from $30 to $30,000. The FDA is criticized for allowing patent exclusivity on existing drugs and failing to protect the public from corporate monopolies.
